三醇:对各种病理状况的有前途的治疗药物
Mahboobeh Ghasemzadeh Rahbardar1, Prashant Kesharwani2, Amirhossein Sahebkar3,4,5
1Clinical Research Development Unit, Shahid Hasheminejad Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Current medical science
|March 6, 2026
概括
天然糖的三糖,由于其细胞保护性质,显示出对代谢障碍,癌症和其他疾病的治疗前景. 需要进一步的研究来确认其在临床应用中的有效性和安全性.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 糖是一种天然存在的二糖体,具有独特的生化特性.
- 它的细胞保护和抗压能力越来越被认为具有治疗潜力.
研究的目的:
- 通过各种疾病来审查三糖的治疗潜力和临床应用.
- 突出三糖在疾病管理中的作用和未来的研究方向.
主要方法:
- 对trehalose现有的临床研究和研究进行文献综述.
- 在疾病模型中分析了三糖的生物化学特性和已证明的影响.
主要成果:
- 糖通过调节葡萄糖和脂质,显示出对代谢障碍 (糖尿病,肥胖) 的潜力.
- 它在癌症治疗,心血管疾病和各种其他疾病 (如骨关节炎和遗传疾病) 中表现有前途.
结论:
- 醇是一种有前途的治疗化合物,具有广泛的应用.
- 需要进一步的研究,包括大规模试验,以优化剂量并确认疗效和安全性.
相关概念视频
Therapeutic Drug Monitoring: Overview and Classification
459
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
459
Therapeutic Drug Monitoring: Affecting Factors
300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300
Transdermal Drug Delivery Systems
79
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
79
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Therapeutic Drug Monitoring: Drug Analysis Methods
253
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
253
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
608
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
608


